HomeTrialNCT05649722
🔬NCT05649722Phase 2Phase 3ACTIVE NOT RECRUITING

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Study Summary

The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-211 (NCT05176951) and other lead-in studies of TPIP in participants with PH-ILD.

View on ClinicalTrials.gov ↗
Study Details
Enrollment31 participants
Primary Completion
Lead SponsorInsmed Incorporated
Data Retrieved2026-04-11 04:17:39.580834+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.